Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-26T07:44:23.074Z Has data issue: false hasContentIssue false

69 - Viral Hemorrhagic Fever

from Part IV - Current Topics

Published online by Cambridge University Press:  15 December 2009

By
David M. Stier ,
Jennifer C. Hunter ,
Olivia Bruch  and
Karen A. Holbrook
Edited by
Rachel L. Chin
David M. Stier
Affiliation:
Medical Epidemiologist, Medical Director, Adult Immunization and Travel Clinic, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
Jennifer C. Hunter
Affiliation:
Research Assistant, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
Olivia Bruch
Affiliation:
Health Program Coordinator, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
Karen A. Holbrook
Affiliation:
Medical Epidemiologist, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
Rachel L. Chin
Affiliation:
University of California, San Francisco
Get access

Summary

INTRODUCTION

Viral hemorrhagic fevers (VHFs) refer to a group of illnesses caused by several families of viruses, including:

  • Filoviridae (Ebola and Marburg viruses)

  • Arenaviridae (Lassa fever and New World hemorrhagic fever)

  • Bunyaviridae (Rift Valley fever, Crimean-Congo fever, and agents of “hemorrhagic fever with renal syndrome” [HFRS])

  • Flaviviridae (yellow fever, Omsk hemorrhagic fever, Kyasanur Forest disease, and dengue)

Many VHF viruses are virulent, and some are highly infectious (e.g., filoviruses and arenaviruses) with person-to-person transmission from direct contact with infected blood and bodily secretions. Effective therapies and prophylaxis are extremely limited for VHF; therefore, early detection and strict adherence to infection control measures are essential.

The Working Group for Civilian Biodefense considers some hemorrhagic fever (HF) viruses to pose a serious threat as potential biological weapons based on their risk of morbidity and mortality, feasibility of production, and their ability to cause infection through aerosol dissemination. These include Ebola, Marburg, Lassa fever, New World arenaviruses, Rift Valley fever, yellow fever, Omsk hemorrhagic fever, and Kyasanur Forest disease. This chapter will focus only on these VHF viruses and will not include a discussion of dengue fever (see Chapter 54, Fever in the Returning Traveler), hemorrhagic fever with renal syndrome (see Chapter 70, Hantavirus), and Crimean-Congo hemorrhagic fevers.

Type
Chapter
Information
Emergency Management of Infectious Diseases , pp. 459 - 468
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Borchert, M, Mulangu, S, Swanepoel, R, et al. Serosurvey on household contacts of Marburg virus. Emerg Infect Dis 2006;12(3):433–9.CrossRefGoogle Scholar
Centers for Disease Control and Prevention (CDC). Yellow fever vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR 2002 Nov 8;51(RR17):1–10.
Centers for Disease Control and Prevention (CDC). Factsheet: Kyasanur Forest Disease. 2002. April 6, 2007. Available at: http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/kyasanur.htm.
Centers for Disease Control and Prevention (CDC). Factsheet: Omsk Hemorrhagic Fever. 2002. April 6, 2007. Available at: http://www.cdc.gov/ncidod/dvrol/spb/mnpages/dispages/omsk.htm.
Centers for Disease Control and Prevention (CDC). Fatal illnesses associated with a New World arenavirus – California, 1999–2000. MMWR 2000;49(31):709–11.
Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Amazonas, Brazil, 2002. MMWR 2000;51(15):324–5.
Centers for Disease Control and Prevention (CDC). Fatal yellow fever in a traveler returning from Venezuela, 1999. MMWR 2000;49(14):303–5.
Centers for Disease Control and Prevention (CDC). Imported Lassa Fever – New Jersey, 2004. MMWR 2004;53(38):894–7.
Centers for Disease Control and Prevention (CDC). Interim guidance for managing patients with suspected viral hemorrhagic fever in U.S. hospitals. 2005. Available at: http://www.cdc.gov/ncidod/dhgp/bp_vhf_interimGuidence.html.
Feldmann, H, Jones, S M, Daddario-Dicaprio, K M, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;19;3(1):e2.CrossRefGoogle Scholar
Geisbert, T W, Hensley, L E, Kagan, E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193(12):1650–7.CrossRefGoogle ScholarPubMed
Geisbert, T W, Jones, S, Fritz, E A, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2005;2(6).CrossRefGoogle ScholarPubMed
Jones, S M, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005;11(7):786–90.CrossRefGoogle ScholarPubMed
Leroy, E M, Kumulungui, B, Pourrut, X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438(7068):575–6.CrossRefGoogle Scholar
Madani, T A, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003;37(8):1084–92.CrossRefGoogle ScholarPubMed
Maiztegui, J I, McKee, K T, Oro, Barrera J G, et al. Protective efficacy for a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 1998;177(2):277–83.CrossRefGoogle ScholarPubMed
Martin, J E, Sullivan, N J, Enama, M E, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006;13(11):1267–77.CrossRefGoogle Scholar
Mupapa, K, Mukundu, W, Bwaka, M A, et al. Ebola hemorrhagic fever and pregnancy. J Infect Dis 1999;179 Suppl 1:S11–2.CrossRefGoogle Scholar
Mupapa, K, Massamba, M, Kibadi, K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999;179(Suppl 1):S18–23.CrossRefGoogle ScholarPubMed
Pattnaik, P. Kyasanur forest disease: an epidemiological view in India. Rev Med Virol 2006 May–Jun;16(3):151–65.CrossRefGoogle Scholar
Peters, C J, LeDuc, J W. An introduction to Ebola: the virus and the disease. J Infect Dis 1999;179(Suppl 1):ix–xvi.CrossRefGoogle ScholarPubMed
Pittman, P R, Liu, C T, Cannon, T L, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans. Vaccine 1999;18(1–2):181–9.CrossRefGoogle ScholarPubMed
Borio, L, Inglesby, T, Peters, C J, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287(18):2391–405.CrossRefGoogle ScholarPubMed
Center for Infectious Disease Research and Policy (CIDRAP). Viral hemorrhagic fever (VHF): current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis. 2006. Retrieved April 6, 2007, from http://www.cidrap.umn.edu/cidrap/content/bt/vhf/biofacts/vhffactsheet.html.
Peters C J. Chapter 164 – Lymphocytic choriomeningitis virus, Lassa virus, and the South American hemorrhagic fevers. In: Mandell, G L, Bennett, J E, Dolin, R, eds, Principles and practice of infectious diseases (6th ed). New York: Churchill Livingstone, 2005.Google Scholar
Peters C J. Chapter 326 – Bioterrorism: viral hemorrhagic fevers. In: Mandell, G L, Bennett, J E, Dolin, R, eds, Principles and practice of infectious diseases (6th ed). New York: Churchill Livingstone, 2005.Google Scholar
Tsai T F, Vaughn D W, Solomon T. Chapter 149 – Flaviviruses (yellow fever, dengue hemorrhagic fever, Japanese encephalitis, West Nile encephalitis, tick-borne encephalitis). In: Mandell, G L, Bennett, J E, Dolin, R, eds, Principles and practice of infectious diseases (6th ed). New York: Churchill Livingstone, 2005.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Viral Hemorrhagic Fever
    • By David M. Stier, Medical Epidemiologist, Medical Director, Adult Immunization and Travel Clinic, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Jennifer C. Hunter, Research Assistant, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Olivia Bruch, Health Program Coordinator, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Karen A. Holbrook, Medical Epidemiologist, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
  • Edited by Rachel L. Chin, University of California, San Francisco
  • Book: Emergency Management of Infectious Diseases
  • Online publication: 15 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511547454.070
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Viral Hemorrhagic Fever
    • By David M. Stier, Medical Epidemiologist, Medical Director, Adult Immunization and Travel Clinic, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Jennifer C. Hunter, Research Assistant, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Olivia Bruch, Health Program Coordinator, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Karen A. Holbrook, Medical Epidemiologist, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
  • Edited by Rachel L. Chin, University of California, San Francisco
  • Book: Emergency Management of Infectious Diseases
  • Online publication: 15 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511547454.070
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Viral Hemorrhagic Fever
    • By David M. Stier, Medical Epidemiologist, Medical Director, Adult Immunization and Travel Clinic, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Jennifer C. Hunter, Research Assistant, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Olivia Bruch, Health Program Coordinator, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA, Karen A. Holbrook, Medical Epidemiologist, Communicable Disease Control and Prevention Section, San Francisco Department of Public Health, San Francisco, CA
  • Edited by Rachel L. Chin, University of California, San Francisco
  • Book: Emergency Management of Infectious Diseases
  • Online publication: 15 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511547454.070
Available formats
×